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Summary
 
We and others have shown that the products of the HLA-DM locus are required for the intra-
cellular assembly of major histocompatibility complex class II molecules with cognate peptides
for antigen presentation. HLA-DM heterodimers mediate the dissociation of invariant chain
(Ii)-derived class II–associated Ii peptides (CLIP) from class II molecules and facilitate the load-
ing of class II molecules with antigenic peptides. Here we describe novel APC mutants with
defects in the formation of class II–peptide complexes. These mutants express class II molecules
which are conformationally altered, and an aberrantly high percentage of these class II mole-
cules are associated with Ii-derived CLIP. This phenotype resembles that of DM null mutants.
However, we show that the defects in two of these new mutants do not map to the DM locus.
Nevertheless, our evidence suggests that the antigen processing defective phenotype in these
mutants results from deficient DM expression. These mutants thus appear to define genes in
which mutations have differential effects on the expression of conventional class II molecules
and DM molecules. Our data are most consistent with these factors mapping to human chro-
mosome 6p. Previous data have suggested that the expression of DM and class II genes are co-
ordinately regulated. The results reported here suggest that DM and class II can also be differ-
entially regulated, and that this differential regulation has significant effects on class II–restricted
antigen processing.
 
C
 
onventional class II molecules of the MHC are poly-
morphic cell surface glycoproteins which bind peptide
Ags and display them on the surface of APC for recogni-
tion by CD4
 
1
 
 T cells. Though MHC class II molecules are
mainly associated with peptides derived from endogenous
proteins (1–3), in terms of host defense, class II molecules
function primarily to display peptides derived from exoge-
nous Ags. The selectivity of class II molecules for exoge-
nous Ags derives from a distinct intracellular trafficking path-
way of class II molecules and distinct intracellular sites in
APC for processing of exogenous Ags (4–7).
In the class II pathway, class II 
 
a
 
 and 
 
b
 
 chains assemble
in the endoplasmic reticulum (ER)
 
1
 
 with the invariant
chain (Ii). A short region of Ii encoded by exon 3 prevents
premature binding of peptides in the ER to class II 
 
a
 
/
 
b
 
 by
sterically blocking the Ag binding groove (8, 9). This por-
tion of Ii also appears to act as a surrogate peptide to pro-
mote egress of nonamer (
 
a
 
/
 
b
 
–Ii)
 
3
 
 complexes out of the
ER (10, 11). Ii targets 
 
a
 
/
 
b
 
–Ii to the endosomal compart-
ments where Ii is selectively removed, in part by acid pro-
teolysis (12–16). The complete dissociation of Ii allows ac-
cess of the 
 
a
 
/
 
b
 
 binding groove to exogenous peptides for
functional 
 
a
 
/
 
b
 
–peptide complex assembly (17). Specialized
intracellular vesicles within APC, termed MIIC (5) or CIIV
(18), have been implicated as putative sites for final Ii disso-
ciation and peptide loading (6, 18–20). Until recently, de-
tails of the molecular nature of peptide loading within this
compartment were unknown.
Using a somatic cell mutant approach, we and others
have shown that the products of the HLA-DM locus have
a critical function in the assembly of MHC class II mole-
cules with cognate peptides (21–24). HLA-DMA and -DMB
genes map to the class II region of the HLA complex (25)
and encode subunits of an unconventional MHC class II
heterodimer. HLA-DM mutants are defective in antigen
processing; although these mutants express normal levels of
class II molecules (22, 26–29), they fail to assemble normal
 
a
 
/
 
b
 
–peptide complexes (30–32). This defect in DM mu-
tants is a direct consequence (33) of an aberrantly high per-
centage of class II molecules that remain complexed with
 
1
 
Abbreviations used in this paper
 
: B-LCL, B-lymphoblastoid cell lines; EMS,
ethyl methane sulfonate; ER, endoplasmic reticulum; Ii, invariant chain;
PI, propidium iodide.
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Ii-derived class II–associated Ii peptides (CLIP) (30–32).
CLIP are a nested set of peptides derived from amino acids
81–104 of Ii. CLIP-class II
 
a
 
/
 
b
 
 complexes are normal in-
termediates in the MHC class II biosynthetic route (34). DM
mutants have a block in a step required for removal of
CLIP from class II molecules. Recently, the DM het-
erodimer has been shown in cell-free systems to catalyze the
dissociation of CLIP from class II molecules, and to facilitate
loading of cognate peptides (23, 35–37). Presumably this ac-
tivity of DM is restricted to the peptide loading compart-
ment(s) of APCs. Indeed, HLA-DM has been shown to
localize intracellularly to MIIC (38, 39). How DM expres-
sion is regulated, how its activity is coordinated with the ex-
pression of conventional class II molecules, and what other
factors might interact in the class II pathway remain impor-
tant unresolved problems. However, recent available data
suggest that the DM genes are regulated coordinately with
class II genes under most conditions (52).
To further analyze the pathway of class II antigen pro-
cessing, we have isolated additional mutant APCs defective
in MHC class II–peptide complex assembly. Here we de-
scribe a set of mutants which display a novel class II–defi-
cient phenotype resembling that of DM mutants. How-
ever, these mutants are complementary with T2, a cell that
is homozygously deleted for HLA-DM and the entire class
II region (34, 40, 41). Therefore, the lesions in these new
mutants cannot be in the HLA-DM genes, and the affected
genes map outside the HLA class II region. We provide ev-
idence that these mutants fail to express sufficient levels of
DM heterodimers to effect normal DM function. The re-
sults suggest that DM and class II can be differentially regu-
lated, and that this differential regulation has significant ef-
fects on MHC class II–cognate peptide assembly.
 
Materials and Methods
 
Cell lines and Derivation of Mutants.
 
Mutants 2.2.93 and 2.7.93,
and mutants 3.6.95 and 3.4.95, were isolated from ethyl methane
sulfonate (EMS) mutagenized 3.1.0/DR3 and 6.3.6/DR3, respec-
tively, by immunoselection with anti-DR3 mAb 7.3.19.1 (42)
and rabbit complement. To derive 3.1.0/DR3 and 6.3.6/DR3, a
1.2-kb DRB1.0301 cDNA was cloned from B-LCL 8.1.6 into
pGEM-4 (Promega Corp., Madison, WI). This was then sub-
cloned into the EcoRI site of pBluescript II KS 
 
1
 
/- (Stratagene
Inc., La Jolla, CA) to make pDR3B1.121. A HindIII/SmaI DRB1.
0301 cDNA fragment from pDR3B1.121 was gel purified and sub-
cloned into the HindIII/ HpaI site of pLNCx, a retroviral expres-
sion vector (43). This was used to obtain clones of the packaging
line PA317 (43) to transduce B-LCL 3.1.0 and 6.3.6. DR3-
expressing clones were obtained by 3-d coculture of B-LCL with
the transfected PA317 packaging line in the presence of 4 
 
m
 
g/ml
polybrene (Sigma Chem. Co., St. Louis, MO). After coculture,
G418 (1 mg/ml) resistant cultures of transduced cells were cloned
and screened by flow cytometry for stable DR3 expression to ob-
tain 3.1.0/DR3 and 6.3.6/DR3. In addition, to derive 6.3.6/
DR3, an EcoRI/BamHI DRB1.0301 cDNA fragment from
pDR3B1.121 was gel purified and subcloned into the EcoRI/
BamHI site of pLxSHD, a similar retroviral expression vector (44)
containing 
 
hisD.
 
 This was used also to derive a clone of the pack-
aging line PA317, which was used to super-infect 6.3.6 for high-
level DR3 expression. Transduced 6.3.6 was doubled selected in
1 mg/ml G418 (GIBCO BRL, Gaithersburg, MD) and 4 mM
 
l
 
-histidinol (Sigma) to obtain a 6.3.6/DR3 clone. Both progeni-
tors were mutagenized with EMS to induce point mutations be-
fore immunoselection (45).
Somatic cell hybrids were prepared by PEG fusion as described
(26) and were selected using methotrexate (2 
 
3
 
 10
 
-7
 
 M) and
G418 (1 mg/ml). All hybrids are uncloned, stable lines. For stable
transfection of 2.7.93 with DMA, 2.7.93 was transduced with a
DMA retroviral packaging line as described for 2.2.93 (22).
2.7.93/DMA and 2.2.93/DMA were obtained by transduction of
2.7.93 and 2.2.93, respectively, with a DMA retroviral packaging
line as described for 2.2.93 (22). Stable clones were obtained by
selection in 4 mM 
 
l
 
-histidinol.
 
Flow Cytometric Analysis.
 
For immunofluorescent flow cy-
tometry, 0.5 
 
3
 
 10
 
6
 
 cells were stained for 1 h at 4
 
8
 
C with saturat-
ing amounts of the indicated mAbs in 50 
 
m
 
l RPMI/5% FBS,
washed and further stained 1 h at 4
 
8
 
C with 1:100 fluoresceinated
goat F(ab
 
9
 
)
 
2
 
 anti–mouse IgG Fc (FITC-GAM) (Sigma). After
staining, cells were washed, resuspended in 25 
 
m
 
g/ml propidium
iodide (PI) for dye exclusion (viability) gating, and run through
FACScan
 
Ò
 
 (Becton-Dickinson) and analyzed with REPROMAN.
Cells in each panel were analyzed in parallel. Histograms repre-
sent immunofluorescence on viable, triple-gated events (forward
scatter FSC, side scatter SSC, and PI exclusion).
 
Antibodies.
 
For indirect immunofluorescent flow cytometry,
primary mAbs used were: mAb L-243 (anti DR, reference 1); mAb
VI-15 (anti-DR, reference 46); mAb UK8.1 (anti-DR3, 5, 6, ref-
erence 47); mAb 62.74 (anti-DR1); mAb 16.23 (anti-DR3; ref-
erence 48); mAb 4AA7 (anti-DQ1, reference 49); mAb 13.3.B4
(anti-DP4.1, reference 50); mAb 1A3 (anti-DQ); mAb SPV-L3
(anti-DQ); mAb B7/21 (anti-DP); mAb W6/32 (anti–class I); mAb
4D12 (which recognizes a TAP-dependent determinant on HLA-B5
class I molecules); mAb CER.CLIP.1 which recognizes Ii-derived
CLIP associated with HLA-DR molecules (51); and mAb I-5
which recognizes CLIP associated with HLA class II molecules
(E. Mellins and Y. Paterson, personal communication). For im-
munoselections, mAb 7.3.19.1 was used. mAb 7.3.19.1 binds an
epitope which blocks mAb 16.23 binding (S.P. Fling unpublished
observations) and, like mAb 16.23, exhibits reduced binding on
DM mutants as a result of peptide-induced serological changes in
HLA-DR3 molecules.
To obtain DM
 
a
 
-specific anti-serum 8338H, a recombinant
fusion protein was constructed by subcloning, from pDMA (22),
a 570-bp cDNA fragment encoding the DM
 
a
 
1 and DM
 
a
 
2 in frame
into pMal-C2 (N.E. Biolabs) for bacterial expression. Recombi-
nant fusion protein was purified as described (NEB Instruction
manual, Version 3.01. Protein fusion and expression system. 1993)
and was used to immunize and boost NZW rabbits for produc-
tion of anti-serum 8338H.
 
MHC Class II Dimer Stability Assays.
 
Western immunoblots
were stained with a combination of mAb DA6.147, which recog-
nizes HLA-DR
 
a
 
 monomers and HLA-DR
 
a
 
/
 
b
 
 dimers (53), and
mAb HB10.A, which recognizes HLA-DR3
 
b
 
 monomers and
HLA-DR
 
a
 
/
 
b
 
 dimers (54). For dimer stability assays, nondena-
tured, NP-40 extracted whole cell lysates were prepared and 1 
 
3
 
10
 
6
 
 cell equivalents per sample were run in SDS-PAGE and trans-
ferred to PVDF. Membranes were stained with mAb followed by
polyclonal rabbit anti–mouse IgG and 
 
125
 
I protein-A.
 
Cell Sorting.
 
To fractionate 2.7.93 into mAb 16.23
 
low
 
 and
mAb 16.23
 
null
 
 subpopulations, 10
 
7
 
 cells of a 2.7.93 clone were
stained with saturating levels of mAb 16.23 in RPMI/5% FBS,
washed and stained with FITC-GAM, and then resuspended in 
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PI for viability gating. Cells were sorted by FACStar
 
Ò
 
 (Becton-
Dickinson) by setting collection gates to collect the 10% of the
stained population expressing the lowest levels, or highest levels, of
the 16.23 epitope to obtain mAb 16.23
 
null
 
 and mAb 16.23
 
low
 
 cells,
respectively. Sorted cells were expanded for 2 wk in RPMI/10%
BCS. Cell lysates from the indicated cell lines were then run in
dimer stability assays and were stained with a combination of mAb
DA6.147 and mAb HB10.A. Subclones of the mAb 16.23
 
low
 
 and
mAb 16.23
 
null
 
 subpopulations were obtained by cloning in soft-agar
and were analyzed for mAb 16.23 expression by indirect flow cy-
tometry.
 
Western Immunoblots.
 
Boiled, detergent (NP-40) extracted
cell lysates from 10
 
6
 
 cells/lane or 0.5 
 
3
 
 10
 
6
 
 hybrids/lane were
prepared and run in reducing SDS-PAGE and transferred as de-
scribed (55). Membranes were stained with anti-DM
 
a
 
 anti-serum
8338H followed by biotinylated goat anti–rabbit IgG (GIBCO
BRL) and Streptavidin-HRP (GIBCO BRL) followed by Lumi-
glo substrate (Kirkegaard and Perry Labs. Gaithersburg, MD).
 
Transient DM Expression Assays.
 
For transient expression ex-
periments, cDNA encoding HLA-DMB and cDNA encoding
HLA-DMA were cloned into the expression vector pcDNAI/AMP
(Invitrogen Corp., Carlsbad, CA) to obtain plasmids pDMB and
pDMA, respectively, as described (22). pcDNAI/AMP contains
Polyoma and SV40 origins of replication, allowing for episomal rep-
lication. For transient transfections, 2.5 
 
3
 
 10
 
7
 
 of the indicated cells
were resuspended in 0.5 ml RPMI with 15–25-
 
m
 
g circular pDMB
or pDMA or both and were electroporated using 2.2 kV. Samples
were cultured for 72 h to regain high viability and then were
stained and analyzed by flow cytometry as described in Fig. 2.
 
Northern Analysis.
 
Total cellular RNA was isolated and
northern blots were prepared by standard techniques (56, 57).
Probes used for hybridization were labeled with [
 
32
 
P]dCTP using
random primers (Boehringer Mannheim Biochemicals, Indianap-
olis, IN). PCR was used to generate full-length probes from DMA
and DMB cDNAs as described (22). The actin probe was a cDNA
in a linearized plasmid (58).
 
Results
 
Derivation of Mutants 2.7.93, 3.6.95, and 3.4.95.
 
EBV
transformed human B-lymphoblastoid cell lines (B-LCL)
with hemizygous MHC deletions have been useful as pro-
genitors for immunoselecting recessive mutants which are
defective in MHC class II/peptide assembly, including DM
mutants previously isolated (21, 22, 26, 27). Using this ap-
proach, we derived mutant 2.7.93 from progenitor 3.1.0,
which contains an 
 
z
 
40-Mb hemizygous deletion in chro-
mosome 6p, removing one HLA haplotype (59) (Fig. 1). Mu-
tants 3.6.95 and 3.4.95 were similarly derived from pro-
genitor 6.3.6, which contains a smaller, 
 
z
 
30 Mb hemizygous
deletion in chromosome 6p, which is overlapped by the
3.1.0 deletion (59) (Fig. 1). As a basis for immunoselection of
these mutants, progenitors 3.1.0 (DR1
 
1
 
/DR3-) and 6.3.6
(DR1
 
1
 
/DR3-) were first transduced with DRB1.0301.
HLA-DR3 molecules exhibit reduced binding of certain
mAbs, e.g., mAb 16.23 and mAb 7.3.19.1, as a result of
changes in occupancy of the peptide binding groove (22,
26). The 3.1.0/DR3 and 6.3.6/DR3 progenitors were mu-
tagenized with EMS and were immunoselected with mAb
7.3.19.1. After immunoselection, surviving clones were
screened for loss of mAb 16.23 binding and further analyzed
for class II alterations suggestive of defects in MHC class II/
peptide assembly. Mutants 2.7.93, 3.4.95, and 3.6.95 were iso-
lated from mutagenized progenitors at frequencies of 
 
z
 
10
 
2
 
4
 
,
consistent with observed frequencies for EMS-induced re-
cessive mutations in other hemizygous loci using equivalent
EMS concentrations and standard protocols (55, 60).
 
Mutants 2.7.93, 3.6.95, and 3.4.95 Express Conformation-
ally Altered MHC Class II Molecules at the Cell Surface.
 
The class II cell surface phenotypes of the new mutants
were characterized by FACS
 
Ò
 
 analysis using a panel of mAbs
Figure 1. Derivation of mu-
tant cell lines. (a) Regions of
chromosome 6p hemizygously
deleted in progenitors 3.1.0
(z40 Mb) and 6.3.6 (z30 Mb)
and their positions relative to the
HLA complex. (b) The HLA class
II region haplotypes of B-LCL
3.1.0, the progenitor of mutant
2.7.93 and mutant 2.2.93 (DMA
null) (22). (c) The HLA class II
region haplotypes of B-LCL
6.3.6, the progenitor of mutants
3.6.95 and 3.4.95. Deletions are
indicated by horizontal hatched
bars on the deleted haplotype
and have been previously de-
scribed for 3.1.0 and 6.3.6 (71).
Vertical bars indicate approxi-
mate locations of genetic loci
and details of the HLA class II
region (72). (d) The 1-Mb class
II region HLA homozygous de-
letion in T2 (T 3 B hybrid line:
721.174 3 CEM.T2) (40). The
centromeres are to the left. Not
to scale. 
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to polymorphic and monomorphic determinants. As shown
in Fig. 2, new mutant 2.7.93 has a pattern of diminished
binding of antibodies to polymorphic class II determinants
which resembles that of DM null mutants. Specificially,
mutant 2.7.93 expresses levels of class II HLA-DR mole-
cules similar to its progenitor 3.1.0/DR3, but exhibits a
major reduction in the binding of DR3-specific mAb 16.23
(Fig. 2 
 
e
 
). Anti-DR3,5,6 mAb UK8.1 staining indicates that
the reduction in expression of the mAb 16.23 determinant
is not a result of loss of DR3B1 transgene expression (Fig. 2 
 
c
 
).
Mutant 2.7.93 also exhibits reductions in the binding of DQ1-
specific mAb 4AA7 and of DP4.1-specific mAb 13.3.B4 (Fig.
2). The pattern of expression of the determinants recog-
nized by these mAbs in mutant 2.7.93 is similar to that seen
in DMA null mutant 2.2.93 (Fig. 2). These determinants,
like that recognized by mAb 16.23, have previously been
shown to be DM dependent (22). Thus the lesion in mu-
tant 2.7.93 extends to determinants on all class II isotypes.
These changes in MHC expression are limited to class II, as
the expression of MHC class I appears unaffected (Fig. 2 
 
h
 
).
Mutants 3.6.95 and 3.4.95 have similar phenotypes to
mutant 2.7.93, although they were derived from a different
progenitor, 6.3.6/DR3 (Fig. 1), and thus are independent
of 2.7.93. Mutants 3.6.95 and 3.4.95, like 2.7.93, exhibit
substantial loss of the mAb 16.23 epitope (Fig. 6 
 
a
 
), but
they also retain levels of MHC HLA-DR and of the DR3
transgene comparable to those of progenitor 6.3.6/DR3
(Table 1).
Although these changes resemble those of DM null mu-
tants, there are features of the mAb binding profile that dis-
tinguish the new mutants from DMA mutant 2.2.93 and all
other DM mutants. In particular, whereas DM null mutants
are essentially mAb 16.23
 
null
 
, mutant 2.7.93 has the mAb
16.23
 
null
 
 peak but also a reproducible mAb 16.23
 
low
 
 shoul-
der (Figs. 2 
 
e
 
 and 5). Mutants 3.4.95 and 3.6.95 also exhibit
this unusual, bimodal distribution of mAb 16.23 staining
(Fig. 6 
 
a
 
), although relative to 2.7.93, mutant 3.4.95 con-
sistently displays a greater proportion of mAb 16.23
 
null
 
 cells
and 3.6.95 consistently displays a greater proportion of mAb
16.23
 
low
 
 cells in their respective populations. Thus, these mu-
tants have related, yet distinguishable phenotypes. The bi-
modal mAb 16.23 staining pattern in these mutants persists
despite repeated subcloning (see below and Fig. 5).
A second significant difference between the new mutants
and DM null mutants is evident from cell surface binding
patterns with a broader panel of class II mAbs, as shown in
Fig. 2 and summarized in Table 1. Whereas DM null mu-
tant 2.2.93 is affected principally in the binding of antibod-
ies recognizing class II polymorphic determinants (the DP
monomorphic determinant recognized by mAb B7/21 be-
ing the only exception), the new mutants are affected not
only for these class II polymorphic determinants but for
class II monomorphic determinants as well. For example,
HLA-DR levels measured by mAb VI.15 and L-243 stain-
ing are diminished (
 
z
 
75% of wild type) on mutant 2.7.93.
This pattern differs from that of a DM null mutant 2.2.93
(also 3.1.0/DR3-derived), in which HLA-DR levels mea-
sured by mAb VI.15 and L-243 staining are virtually un-
changed (reference 22 and Table 1). In addition, the ex-
pression on mutant 2.7.93 of DQ determinants recognized
by mAbs SPVL3 and 1A3 is 
 
z
 
25–50% of wild type, and is
reduced to levels lower than in DMA null mutant 2.2.93
(Table 1).
In summary, both DM-dependent and DM-independent
class II cell surface epitopes are affected in the new mutants.
However, there is a greater reduction in the expression of
DM-dependent as compared to DM-independent epitopes.
These data suggest that the genetic lesions in these mutants
have pleiotropic effects: a major effect on DM activity and
a lesser effect in cell surface class II expression.
 
Mutants 2.7.93, 3.6.95, and 3.4.95 Express MHC Class
II Molecules Which Are Unstable in SDS.
 
To assess the ex-
tent of cognate peptide binding to class II molecules in these
new mutants, we analyzed the stability of their class II dimers
in SDS. Cognate peptide binding to class II molecules in-
duces conformational changes in class II dimers which en-
hance their stability in SDS (61–63). Thus, impaired cognate
Figure 2. Mutant 2.7.93 expresses conformationally altered class II mole-
cules. Cell surface staining of MHC molecules on mutant 2.7.93. Mutant
2.7.93 (dark line), its progenitor, 3.1.0/DR3 (thin line), control DMA null
mutant, 2.2.93 (heavy dashed), and negative control, T2 (thin dashed), were
stained in indirect immunofluorescent flow cytometry using class II con-
formation-independent mAbs: (a) L-243 (anti-DR); (b) VI-15 (anti-DR);
(c) UK8.1 (anti-DR3, 5, 7); (d) 62.74 (anti-DR1); and class II conforma-
tion-sensitive mAbs: (e) 16.23 (anti-DR3); (f) 4AA7 (anti-DQ1); (g)
13.3.B4 (anti-DP4.1); and mAb to class I: (h) W6/32. Only mutant 2.7.93
is labeled to highlight its profile. In b only, T2 is heavy dashed and 2.2.93
is thin dashed.1473 Fling et al.
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peptide binding in DM null mutants results in the expres-
sion of SDS unstable class II dimers. Class II dimers from
2.7.93, like class II DR dimers from DM mutants, dissoci-
ate into DRa and DRb monomers in SDS-PAGE, whereas
dimers extracted from progenitor 3.1.0/DR3 remain stable
(Fig. 3). Similarly, dimers from mutants 3.6.95 and 3.4.95,
but not progenitor 6.3.6/DR3, dissociate into DRa and
DRb monomers in SDS-PAGE (data not shown). Nota-
bly, these changes in dimer stability are less severe than in
DM null mutants (see Fig. 5 a) suggesting that the factor(s)
required for class II–peptide complex assembly are signifi-
cantly reduced, but not entirely absent in these mutants.
MHC Class II Molecules from Mutants 2.7.93, 3.6.95, and
3.4.95 Are Associated with Increased Levels of CLIP Pep-
tides. The altered conformation of class II dimers ex-
pressed by these new mutants is similar to that of DM null
mutants, in which the alterations in class II conformation
result from the presence of CLIP and the absence of cog-
nate peptides in the binding groove. To determine if the
new mutants express aberrantly high levels of CLIP–class II
complexes, we measured cell surface levels of CLIP using
mAbs CER.CLIP1 and mAb I-5, both of which recognize
CLIP associated with MHC class II molecules. Mutants
2.7.93, 3.4.95, and 3.6.95, like DM null mutants, exhibit
marked increases in cell surface levels of class II molecules
associated with CLIP peptides (Figs. 4 b and 6 b). However,
the levels of anti-CLIP staining on these mutants are not as
high as those of DM null mutants 2.2.93 or 9.5.3 (Figs. 4
and 6).
Class II Dimer Stability Correlates with mAb 16.23 Staining
in 2.7.93 Subpopulations. An interesting aspect of the
2.7.93-type mutants is the bimodal distribution of mAb 16.23
staining described above. To determine if this unusual dis-
tribution of mAb 16.23 staining correlates with different
levels of class II stability in SDS, we sorted mutant 2.7.93 by
FACSÒ into mAb 16.23null and mAb 16.23low subpopula-
tions. Cell lysates from these two subpopulations were then
run in dimer stability assays. As demonstrated in Fig. 5 a, mAb
16.23null and mAb 16.23low subpopulations of 2.7.93-type
mutants express different levels of stable HLA-DR dimers.
Whereas the majority of HLA-DR molecules in both sub-
populations are in an SDS-unstable state, there is a signifi-
cantly higher proportion of stable HLA-DRa/b dimer in
the mAb 16.23low than in the mAb 16.23null subpopulation.
Therefore, the level of expression of the mAb 16.23 epi-
tope in these mutants correlates with the level of expression
of stable dimers. Insofar as class II dimer stability in SDS is a
measure of DM activity, the bimodal mAb 16.23 pheno-
type of these may result from variable levels of DM expres-
sion.
The Phenotype of 2.7.93-type Mutants Appears Genetically
Stable. The bimodal phenotype of the new mutants ap-
pears genetically stable, in that mutants maintain their char-
acteristic bimodal distribution in continuous culture (data
not shown). Furthermore, the bimodal distribution of the
mAb 16.23 epitope is regenerated in sub-clones of both
mAb 16.23null and mAb 16.23low sorted subpopulations.
This was demonstrated by isolating sub-clones of the mAb1474 Novel HLA-DM Expression Mutants
16.23 sorted subpopulations and analyzing them for mAb
16.23 expression. All sub-clones from both populations re-
veal a variable, but bimodal distribution of mAb 16.23
staining (Fig. 5 b). Within sub-clones, changes in the per-
cent distribution of cells into either population are slow, on
the order of 1–5% per week of continuous culture (data not
shown). While the proportion of cells in each subpopula-
tion varies, the overall phenotype is stable. Finally, it should
be noted that the mean mAb 16.23 staining of the mAb
16.23low subpopulations in these mutants is consistently
,50% of the mean of that of the progenitors (Figs. 2 e and
6 a).
The HLA Class II Homozygous Deletion Mutant T2 Com-
plements the Defect in the New Mutants 2.7.93 and 3.6.95.
3.1.0 and 6.3.6, the progenitors of the new mutants, con-
tain large hemizygous deletions of chromosome 6p which
encompass the HLA-DMA and DMB loci (Fig. 1). Thus,
the DM genes could be considered candidate site for the
mutations because only a single mutational hit in a gene map-
ping to the hemizygous region would generate a recessive
phenotype. However, as described above, these mutants
manifest subtle characteristics distinct from those of DM
null mutants. Preliminary observations also suggested that the
lesions in these new mutants might not be in the HLA-DM
genes. We observed that 2.7.93 and the DMB null mutant
9.5.3 are complementary in somatic cell fusions (2.7.93 3
9.5.3 lane in Fig. 3, and data not shown). In addition, stable
transduction of 2.7.93 with DMA alone, using a retroviral
vector containing a DMA cDNA, fails to complement the
2.7.93 defect (data not shown), though this same construct
complements the DMA null mutant 2.2.93 (22). These
data tended to exclude mutations in either DMA or DMB
alone.
To determine if the mutations of the new mutants map
to either the DMA or DMB locus, we made stable somatic
cell hybrids between 2.7.93 and T2, and between 3.6.95
and T2. T2 is homozygously deleted for the entire class II
region (41) (Fig. 1) and can contribute neither conven-
tional class II molecules nor DM molecules to somatic cell
hybrids. Control hybrids between a 3.1.0/DR3-derived DM
null mutant 2.2.93 and T2 are noncomplementary (Fig. 6),
as expected. However, both mutants 2.7.93 and 3.6.95 are
complemented by T2 in somatic cell hybrids. This is evi-
denced by restoration to wild-type levels of mAb 16.23
binding (Fig. 6), by a dramatic reduction to wild-type lev-
els of cell surface CLIP (Fig. 6), and by the appearance of
SDS-stable class II dimers in cell lysates from these hybrids
(data not shown). Therefore, the lesions in these new mu-
tants are recessive, cannot be in the HLA-DM genes, and
Figure 3. Mutant 2.7.93 ex-
presses unstable class II dimers,
and the defects in dimer stability
in mutant 2.7.93 and DM mu-
tant 9.5.3 are complementary.
Cell lysates from mutant 2.7.93,
and the indicated control cell
lines, DMA mutant 2.2.93 and
DMB mutant 9.5.3, and lysates
from somatic cell hybrids were
run in dimer stability assays es-
sentially as described (55). West-
ern blots were stained with a combination of mAb DA6.147, which rec-
ognizes DRa monomer and DRa/b dimers, and HB10.A, which reacts
with DR3b1 and DR3b3 in monomeric form and in DRa/b dimers.
Figure 4. Mutant 2.7.93 expresses increased levels of class II which are
associated with CLIP. (a) Control cells, DMA null mutant 2.2.93 and
DMB null 9.5.3, their progenitors 3.1.0/DR3 and 8.1.6, and negative
control T2, were stained in indirect immunofluorescent flow cytometry
with mAb CER.CLIP.1, which recognizes CLIP associated with HLA-
DR molecules. (b) Mutant 2.7.93, control cell DMA mutant 2.2.93, their
progenitor, 3.1.0/DR3, and negative control T2, were stained in indirect
immunofluoresence with mAb CER.CLIP.
Figure 5. mAb 16.23null and
mAb 16.23low sorted subpopula-
tions of 2.7.93-type mutants ex-
press differential levels of stable
HLA-DR dimers. (a) SDS stabil-
ity of HLA-DR molecules from
cell-sorted mAb16.23null and
mAb 16.23low subpopulations of
mutant 2.7.93. Western blots
were stained with a combina-
tion of mAbs DA6.147 and
HB10.A. (b) Bimodal reexpres-
sion of the mAb 16.23 epitope in
subclones of the 2.7.93 mAb
16.23null sorted subpopulations.
2.7.93 cells were stained in indi-
rect immunofluorescence with
mAb 16.23. Each panel repre-
sents mAb 16.23 staining of an individual subclone of 2.7.93 (mAb 16.23null); subclones of the mAb 16.23low subpopulation show similar bimodal reex-
pression of the mAb 16.23 epitope (data not shown).1475 Fling et al.
map outside the 1 Mb HLA class II region. To verify that
these somatic hybrids contain the MHC haplotypes of both
input partners, we stained them and controls with the
TAP-dependent, HLA-B5–specific antibody mAb 4D12.
Stable hybrids 2.7.93 3 T2 and 3.6.95 3 T2 each express
the epitope recognized by mAb 4D12 (data not shown).
This reciprocal complementation of the TAP defect in T2
by the 2.7.93 and 3.6.93 partners can only be achieved in
trans by contributions from both the T2 (TAP2; B51) and
2.7.93 or 3.6.95 (TAP1; B52) MHC haplotypes. Thus,
these somatic hybrids contain the chromosome 6p haplo-
types of both input partners. Stable hybrids between 3.4.95
and T2 have not yet been obtained.
Mutants 2.7.93, 3.6.95 and 3.4.95 Express Diminished
Levels of DM Proteins. The T2 complementation results
indicate that the lesion(s) in these new mutants map outside
the HLA class II region and thus are neither in the HLA-DM
structural genes nor in cis-acting DM regulatory elements.
Because the phenotype of these mutants resembles that of
DM null mutants, these mutants might have regulatory le-
sions affecting the expression of DM which could explain
their unusual phenotype. Western immunoblots of lysates
from the mutants and their progenitors were stained with
rabbit polyclonal antisera against DMa (Fig. 7) and DMb
(data not shown) to assess relative levels of DM protein ex-
pression. Mutant 2.7.93 expresses no detectable DMa mono-
mer; mutants 3.6.95 and 3.4.95 exhibit significantly re-
duced (1/5 to 1/10 of wild type) levels of DMa monomer
(Fig. 7). Western blots with rabbit polyclonal antiserum
raised against DMb cytoplasmic tail similarly reveal that
mutants 2.7.93, 3.6.95, and 3.4.95 have reduced DMb
monomer (data not shown). This suggested that the pheno-
type of these mutants could be explained by deficient DM
expression.
DMa monomer is increased in western immunoblots in
lysates from 2.7.93 3 T2 and 6.95 3 T2 hybrids (Fig. 7),
consistent with the ability of T2 to complement the other
phenotypic defects in these mutants, as shown above. Be-
cause T2 cannot contribute DM molecules in these somatic
cell hybrids, the restoration of DM expression must result
from provision of a transactive factor by T2.
Both HLA-DMA and -DMB Are Required to Complement
the 2.7.93 Defect. As shown above, both DMA and DMB
proteins are significantly reduced in 2.7.93, and increased
levels of these proteins are observed in lysates made from
hybrids of mutants 3 T2. Therefore, we asked if transfec-
tions of DMA and DMB driven by heterologous promotors
could alter the 2.7.93-type mutant phenotype. In transient
transfection assays, cell surface expression of the mAb 16.23
epitope on mutant 2.7.93 was significantly enhanced by trans-
fection of both DMA and DMB in combination, but not
Figure 6. Cell surface staining of MHC class II and MHC class II/CLIP
complexes on 3.4.95 and 3.6.95, and on (2.7.93 3 T2) and (3.6.95 3
T2). (a and b) Cell surface expression of the mAb 16.23 epitope and of
MHC class II–CLIP complexes on 6.3.6/DR3-derived mutants 3.4.95
and 3.6.95. (a) Negative control DMA null mutant 2.2.93, mutants 3.6.95
and 3.4.95, and progenitor 6.3.6/DR3, were stained by indirect immu-
nofluorescence with mAb 16.23. Subclones of 3.4.95 and 3.6.95 manifest
consistent bimodal expression of the mAb 16.23 epitope as seen in mutant
2.7.93 (data not shown). (b) Negative control 6.1.6 (71), progenitor 6.3.6/
DR3, positive control, DMA null mutant 2.2.93, and mutants 3.6.95 and
3.4.95, were stained by indirect immunofluorescence with anti-class II–
CLIP mAb I-5, which with HLA class II molecules. (c–f) Cell surface ex-
pression of the mAb 16.23 epitope and of MHC class II–CLIP complexes
on somatic cell hybrids. (c) Negative control hybrid (2.2.93 3 T2), posi-
tive control hybrid (3.1.0/DR3 3 T2), and hybrids (2.7.93 3 T2) and
(3.6.95 3 T2); and (d) control hybrid (3.1.0/DR3 3 T2); and hybrids
(2.7.93 3 T2) and (3.6.95 3 T2) and mutants 2.7.93 and 3.6.95; and (e
and f) negative control (T2), negative control somatic cell hybrids (2.2.93 3
T2), positive control hybrids (3.1.0/DR3 x T2); and hybrids (2.7.93 3
T2) were stained in indirect immunofluorescent flow cytometry using the
indicated mAbs.
Figure 7. DM protein levels are reduced in 2.7.93-like mutants.Whole
cell lysates from the indicated cells and somatic cell hybrids were run in
denaturing SDS-PAGE and analyzed in Western immunoblots by staining
with 8338H, a rabbit polyclonal anti-DMa antiserum which recognizes
HLA-DMa monomer, as described in Materials and Methods.1476 Novel HLA-DM Expression Mutants
by transfection of DMA or DMB individually, (Table 2).
This is consistent with the finding that stable transfection of
2.7.93 with DMA cDNA alone failed to complement the
2.7.93 defect. Furthermore, this result is consistent with the
complementation observed between 2.7.93 and the DMB
mutant 9.5.3 (data not shown).
Mutants 2.7.93, 3.6.95, and 3.4.95 Express Diminished
Levels of DM mRNA. The transfection results, described
above, suggested that DM mRNA levels might be deficient
in these mutants. Therefore, DM mRNA levels in the mu-
tants were analyzed by Northern blotting (Fig. 8). These
studies confirmed that DM levels were altered in the mu-
tants, and also indicated a phenotypic difference between
2.7.93 on the one hand, and mutants 3.4.95 and 3.6.95 on
the other. In 2.7.93, both DMA and DMB levels were
markedly reduced, to 10–20% of the levels of progenitor
3.1.0/DR3 (Fig. 8, and data not shown). In mutants 3.4.95
and 3.6.95, DMB levels were likewise reduced to the
z10% level, but DMA levels were only modestly reduced.
Thus, the primary defect in 2.7.93 appears to be a reduc-
tion in both DMA and DMB mRNAs whereas in 3.4.95
and 3.6.95 the principal defect appears to be a reduction in
DMB mRNA. These reductions in DM mRNAs provide a
reasonable basis for the reductions in DM protein and the
secondary manifestations of DM deficiency in the mutants,
described above. It is likely that the reduction in DMa
protein in 3.4.95 and 3.6.95 results in part from accelerated
turnover of DMa protein beacause of the relative defi-
ciency of the DMb subunit, as is common when one sub-
unit of a dimeric protein is absent (74).
Discussion
The molecular requirements for the association of anti-
genic peptides with MHC class II molecules have been
more clearly elucidated in the past few years. In particular,
the accessory molecule HLA-DM has been shown to pro-
vide a critical role in the maturation of functional class II–
peptide complexes (21, 22, 24, 54). However, the factors
involved in regulating DM expression and its catalytic ac-
tivity remain to be determined. The importance of DM in
proper class II presentation, the presence of typical class II
promotor elements in the DM regulatory regions, and the
fact that g-interferon induces DM expression, all imply co-
ordinate expression of DM with other class II molecules.
We describe here a set of novel APC mutants which ex-
hibit discoordinate expression of conventional MHC class
II molecules and the accessory molecule HLA-DM.
The mutants described in this paper have a phenotype
that bears a marked resemblance to that of DM null mu-
tants. In particular, their cell surface class II molecules are
predominantly associated with CLIP. Our data also suggest
that the phenotype of these mutants directly results from a
deficiency in DM expression. However, the defects in two
of the mutants tested so far do not map to the HLA-DM
loci; in somatic cell hybrids, these mutants are complemen-
tary with T2, a fusion partner that contains a homozygous
deletion encompassing HLA-DMA and -DMB and the en-
tire HLA class II region. Thus the lesions for 2.7.93 and
3.6.95 cannot be in the HLA-DMA or -DMB structural
genes nor in any genes in the class II region, including the
conventional class II genes. Complementation of the mu-
tant defect in trans with T2 also rules out mutations in DM
cis-regulatory regions.
The locations of the genes affected in these mutants are
not known with certainty. However, their observed fre-
quency in EMS mutagenized progenitors 3.1.0 and 6.3.6 is
z1024; this is the expected frequency for monozygous loss,
and is several orders of magnitude higher than expected for
dizygous loss (60). Thus, the genetic lesions in these mu-
tants most likely map to the regions of hemizygous dele-
tions in 3.1.0 and 6.3.6. The hemizygous deletions in 3.1.0
Table 2. Transient DM Expression Assay: Restoration of the mAb 16.23 Epitope
Cells Genotype
Transfected DNA
(Transient) No. trials
D %16.231
cells*
2.2.93‡ DMA2/2 pDMA n 5 15 4–19
2.2.93 DMA2/2 pDMB n 5 15 0
9.5.3‡ DMB2/2 pDMA n 5 12 0
9.5.3 DMB2/2 pDMB n 5 12 3–15
2.7.93 ?? pDMA n 5 30
2.7.93 ?? pDMB n  5 20
2.7.93 ?? pDMA  1 pDMB n 5 11 1
2.7.93/DMA§ DMA wt pDMB n 5 2 11–13
*Cells were stained and analyzed by indirect immunofluorescent flow cytometry: D%16.231 cells 5 % cells in R2 (mAb 16.231) of test population 2%
cells in R2 of negative control (untransfected) population.
‡DM null mutants 2.2.93 and 9.5.93 (22) included as controls.
§2.7.93 stably transduced with DMA.1477 Fling et al.
and 6.3.6 encompass z40 Mb and z30 Mb, respectively,
of chromosome 6p (Fig. 1); therefore the affected gene(s)
likely map to these regions of chromosome 6p, but outside
the class II region.
Although the defects in mutants 2.7.93 and 3.6.95 do
not map to the DM loci, the dramatic reductions in DM
proteins and mRNAs suggest that their phenotype results
from deficient DM expression. This is evidenced by the
fact that class II molecules are expressed but are unstable in
SDS, that class II molecules remain complexed with CLIP
peptide, and that there is a marked reduction of DM-
dependent mAb epitopes on class II molecules which ex-
ceeds the reduction in class II levels. Thus, class IIa/b–Ii
complexes are being expressed in the absence of adequate
levels of DM for removal of CLIP. Consistent with this,
transient transfections of 2.7.93 with DMA and DMB to-
gether, but not singly, lead to an increase in the level of
mAb 16.23 binding (Table 2). Although all measures of
DM activity indicate that each mutant has a major defi-
ciency in DM expression, the lesions also modestly affect
class II expression, as indicated by the decreased levels of
cell surface class II molecules (Fig. 2 and Table 1) and class
II mRNA’s (Muczynski, K., and B. Arp, unpublished
data). These reductions in class II expression are generally
not seen in DM structural gene mutants, such as mutant
2.2.93 (Table 1). It appears from these results that the le-
sions in the new mutants differentially affect DM versus
conventional class II expression.
The complementation data suggest that the dispropor-
tionate loss of DM expression relative to conventional class II
expression in these mutants results from recessive mutations
in a transactive factor(s). Previous reports have indicated
that DM and class II genes are coordinately regulated. Both
class II and HLA-DM transcription are induced by IFN-g
(25, 64, 65), and it has been proposed that the S-X-Y reg-
ulatory regions of DM genes function similarly to class II
regulatory elements (52). Furthermore, HLA-DM and con-
ventional class II transcription are coordinately regulated in
all known cases of class II immunodeficiency (66), in in
vitro class II transcription mutants (67, 68), and in mutants
defective in IFN-g–induced class II transcription (69). The
mutants described here thus provide evidence suggesting
that DM and class II expression can be differentially regu-
lated by a trans-acting factor. The existence of an MHC
class II isotype-specific trans-acting factor has also been re-
cently described for HLA-DQ (73).
While mutants 2.7.93, 3.6.96, and 3.4.95 all express es-
sentially undetectable levels of DMB mRNA, they express
different levels of DMA mRNA, suggesting that different
transactive factors may be affected in this set of mutants.
Consistent with this, preliminary complementation studies
suggest that at least two different factors are affected in the
three mutants (Rak, J., unpublished data). How these fac-
tors differentially regulate DM and class II mRNA abun-
dance is currently under investigation.
Perhaps the most surprising and distinguishing aspect of
the mutants described here is the bimodal mAb 16.23 stain-
ing pattern observed in clonal populations. Our data show
that expression of the mAb 16.23 epitope on DR3 mole-
cules on these mutants is distributed into distinct 16.23null
and 16.23low sub-populations. This bimodal mAb 16.23
staining profile is specific for the DR3 expressed by these
mutants; it is not observed with other DM sensitive mAbs
to DQ and DP, nor with mAbs recognizing class II-CLIP.
Altered levels of expression of the mAb 16.23 determinant
by sub-populations of these mutants do, however, correlate
with differences in other measures related to DM activity,
i.e., SDS-stability of both DR1 and DR3 dimers (Figs. 3,
5) and of DQ and DP dimers (data not shown). Thus, the
bimodality observed for 16.23 expression by these mutants
is most likely related to their reduced levels of DM expres-
sion. This is consistent with preliminary data which indi-
cate that the bimodality for the 16.23 epitope in 2.7.93 is
correlated with bimodality for DM expression (Anderson,
S., S. Fling, and D. Pious, manuscript in preparation). The
biphasic phenotype is suggestive of a threshold effect at the
level of DM expression.
The bimodal expression of a DM-dependent, DR3 class
II determinant is not unprecedented; it is similar to that de-
scribed for T2/DR3 transfected with DM (51). Clonal
populations of T2/DR3 transfected with DM also stain in a
bimodal distribution with a DM-sensitive mAb, in this case
mAb CER.CLIP.1 (51). This bimodal profile is specific for
DR3 expressed in T2; it is not observed in T2/DR4 nor
T2/DR11. As with the staining profile of the mutants de-
scribed here, the bimodal staining profile of T2/DR3/DM
with the DM-sensitive mAb CER.CLIP.1 cannot be re-
moved by repeated subcloning (51). Anti-CLIP staining on
the mutants described here is not distributed into clearly
Figure 8. DMA and DMB mRNA levels are reduced in 2.7.93-like
mutants. Total cellular RNA from the indicated cells were analyzed in
Northern blots. Full-length probes from DMA and -B cDNAs were la-
beled with [32P]dCTP and used for hybridization. Reprobing of North-
erns with actin (not shown) indicated equal loading of RNA to all lanes.1478 Novel HLA-DM Expression Mutants
distinct CLIP1/2 subpopulations, unlike anti-CLIP stain-
ing on T2/DR3/DM. This difference most likely results from
the ability of the anti-CLIP mAbs used in our study to rec-
ognize CLIP in association with each of the four class II al-
leles (DR1, DR3, DQ1, DP4.1) expressed by these mu-
tants; in contrast, T2/DR3/DM expresses only DR3. The
bimodal distribution of DM-dependent epitopes seen spe-
cifically on DR3 molecules in these mutants and in T2/
DR3/DM could be related and may suggest that the re-
quirements for DM may differ for DR3 and other class II
molecules. Differences between DR3 and other class II
molecules in their respective affinities for CLIP have been
shown (70).
The mutants described in this report appear to define a
gene or genes required to maintain coordinated expression
of HLA-DM and conventional class II molecules in APC.
For the majority of cells in a clonal population of these mu-
tants, the expression of DM appears to be below a thresh-
old required to remove CLIP from class II molecules, and
to catalyze their loading with cognate peptides. Overall, our
data show that even modest perturbations in the coordi-
nated expression of DM and class II can result in profound
differences in the level of functional class II–peptide com-
plexes ultimately expressed by APC. The significant influ-
ence of DM on the spectrum of peptides associated with
MHC class II suggests the interesting possibility that such
dysregulation of DM expression may contribute to some
level of immune dysfunction. Identification of the factors
deficient in these mutants should help to identify compo-
nents which regulate expression of DM. That the genes de-
fective in these mutants have effects on both DM and class
II expression suggests the defective genes may also regulate
other components of the MHC class II antigen processing
pathway.
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